Abstract

We conducted an observational study from January 2016 through January 2017 of patients admitted to a reference pediatric hospital in Madrid, Spain, for neurologic symptoms and enterovirus infection. Among the 30 patients, the most common signs and symptoms were fever, lethargy, myoclonic jerks, and ataxia. Real-time PCR detected enterovirus in the cerebrospinal fluid of 8 patients, nasopharyngeal aspirate in 17, and anal swab samples of 5. The enterovirus was genotyped for 25 of 30 patients; enterovirus A71 was the most common serotype (21/25) and the only serotype detected in patients with brainstem encephalitis or encephalomyelitis. Treatment was intravenous immunoglobulins for 21 patients and corticosteroids for 17. Admission to the pediatric intensive care unit was required for 14 patients. All patients survived. At admission, among patients with the most severe disease, leukocytes were elevated. For children with brainstem encephalitis or encephalomyelitis, clinicians should look for enterovirus and not limit testing to cerebrospinal fluid.

Highlights

  • Carmen Niño Taravilla,1 Isabel Pérez-Sebastián,1 Alberto García Salido, Claudia Varela Serrano, Verónica Cantarín Extremera, Anna Duat Rodríguez, Laura López Marín, Mercedes Alonso Sanz, Olga María Suárez Traba, Ana Serrano González

  • Epidemiologic Data During the study period, 42 patients were hospitalized for suspected enterovirus neurologic disease

  • Cardiorespiratory failure developed in 3 patients; 1 experienced cardiac arrest, which was reversed with advanced cardiopulmonary resuscitation maneuvers. For those who experienced them, fever and neurologic signs started a median of 3 days (IQR 1.25–5 days) before hospitalization

Read more

Summary

Introduction

Carmen Niño Taravilla, Isabel Pérez-Sebastián, Alberto García Salido, Claudia Varela Serrano, Verónica Cantarín Extremera, Anna Duat Rodríguez, Laura López Marín, Mercedes Alonso Sanz, Olga María Suárez Traba, Ana Serrano González. In support of improving patient care, this activity has been planned and implemented by Medscape, LLC and Emerging Infectious Diseases. LLC designates this Journal-based CME activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)TM. All other clinicians completing this activity will be issued a certificate of participation. To participate in this journal CME activity: [1] review the learning objectives and author disclosures; [2] study the education content; [3] take the post-test with a 75% minimum passing score and complete the evaluation at http://www.medscape.org/journal/eid; and [4] view/print certificate. MD, Clinical Professor, Health Sciences, Department of Family Medicine, University of California, Irvine School of Medicine, Irvine, California. MD, FAAFP, has disclosed the following relevant financial relationships: served as an advisor or consultant for Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Shire Pharmaceuticals; and Sunovion Pharmaceuticals Inc.; served as a speaker or a member of a speakers bureau for Shire Pharmaceuticals

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call